Multidisciplinary Dissection of Renal and Metabolic Effects of Glyfozines on Elderly Patients: From Molecular Aspects to Clinical Indications

The project aims to study the impact of SGLT2i therapy on clinical and biochemical aspects. in elderly. The project will combine different types of data, such as clinical and biological information, and will use advanced Bayesian statistical methods to understand the relationship between risk factors and patient outcomes following treatment with SGLT2 inhibitors.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Elderly Patients (>65 Years) Cardiovascular Diseases Diabetes (DM) Diabetes Mellitus Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Glucose Metabolism Disorders Heart Disease Heart Diseases Internal Disease Kidney Diseases Male Urogenital Diseases Metabolic Diseases Nutritional and Metabolic Diseases Renal Diseases Urogenital Diseases Urologic Diseases

Age range

65 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

San Raffaele Hospital

Milan, 20132, Italy

Location status: Recruiting

Location contact

Chiara Livia CLL Lanzani, professor

PRINCIPAL_INVESTIGATOR

Chiara Livia Lanzani, professor

CONTACT

[email protected]

00390226438131

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Participant is willing and able to give informed consent for participation in the study;
Patients must be enrolled also in MED-Cli e MED-Mol studies by signing both the MED-Cli e MED-Mol informed consents.
The medical product is the standard of care for the patient and has been prescribed according to clinical practice and independent of the present study;
Age ≥65 years;
Participant has not yet started the prescribed SGLT2i therapy;
Participant has at least one clinical indication for SGLT2i use according to clinical practice guidelines.

Exclusion criteria

Current or previous use of SGLT2i;
Inability to sign the informed consent.

Treatment and study plan

Primary outcomes

Patient health status prior and after 6 months of SGLT2i therapy through Frailty Index variation (FI)

Time frame: From enrollment to 6 months

Patient health status prior and after 6 months of SGLT2i therapy through Frailty Index variation (FI).

The FI is score measured by comparing the ratio of health deficits present within an individual to possible health deficits, using a pre-specified list of 30 or more deficits.

Deficits included in the model will be collected during the visit trough questionnaires and clinical and biochemical evaluation

Study contacts

Contact information is provided by the study sponsor or research team.

Chiara Livia Lanzani, professor

CONTACT

[email protected]

00390226438131

Federica Guerra, Dr

CONTACT

[email protected]

00390226438131

Sponsors and collaborators

Lead sponsor

Chiara Lanzani

Other

Registry information

Important dates

Study start: 2025
Primary completion: 2026
Study completion: 2027
First posted: Aug 13, 2025
Registry last updated: Aug 13, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting